NP_005205.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
24,656 Da
NCBI Official Full Name
cytotoxic T-lymphocyte protein 4 isoform CTLA4-TM
NCBI Official Synonym Full Names
cytotoxic T-lymphocyte-associated protein 4
NCBI Official Synonym Symbols
CD; GSE; GRD4; CD152; CTLA-4; IDDM12; CELIAC3 [Similar Products]
NCBI Protein Information
cytotoxic T-lymphocyte protein 4; CD152 isoform; celiac disease 3; cytotoxic T-lymphocyte antigen 4; insulin-dependent diabetes mellitus 12; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
UniProt Protein Name
Cytotoxic T-lymphocyte protein 4
UniProt Synonym Protein Names
Cytotoxic T-lymphocyte-associated antigen 4
UniProt Synonym Gene Names
UniProt Entry Name
CTLA4_HUMAN
NCBI Summary for CTLA4
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. [provided by RefSeq, Jul 2008]
UniProt Comments for CTLA4
CTLA-4: Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE). SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system. Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism. Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12). A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3). It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive. 4 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral; Immunoglobulin superfamily
Chromosomal Location of Human Ortholog: 2q33
Cellular Component: Golgi apparatus; perinuclear region of cytoplasm; integral to plasma membrane; plasma membrane; clathrin-coated endocytic vesicle; external side of plasma membrane
Molecular Function: protein binding
Biological Process: B cell receptor signaling pathway; negative regulation of T cell proliferation; positive regulation of apoptosis; negative regulation of regulatory T cell differentiation; T cell costimulation; negative regulation of immune response; immune response; negative regulation of B cell proliferation; response to DNA damage stimulus
Disease: Autoimmune Lymphoproliferative Syndrome, Type V; Celiac Disease, Susceptibility To, 3; Diabetes Mellitus, Insulin-dependent, 12; Systemic Lupus Erythematosus; Hashimoto Thyroiditis
Research Articles on CTLA4
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with CTLA4 elisa kit
Pathways associated with CTLA4 elisa kit
Diseases associated with CTLA4 elisa kit
Organs/Tissues associated with CTLA4 elisa kit
|